ID: h-6c83282d
Hypothesis

Gut Barrier Permeability-α-Synuclein Axis Modulation

Dysbiotic bacteria compromise intestinal barrier integrity through zonulin pathway activation, allowing bacterial antigens and α-synuclein oligomers to enter systemic circulation and seed CNS pathology.
🧬 CLDN1, OCLN, ZO1, MLCK🩺 neurodegeneration🎯 Composite 53%💱 $0.53▼24.0%proposed
EvidencePending (0%)📖 34 cit🗣 1 debates 5 support 2 oppose
✓ All Quality Gates Passed
Mechanistic 0.70 (15%) Evidence 0.60 (15%) Novelty 0.60 (12%) Feasibility 0.40 (12%) Impact 0.70 (12%) Druggability 0.50 (10%) Safety 0.50 (8%) Competition 0.70 (6%) Data Avail. 0.50 (5%) Reproducible 0.60 (5%) KG Connect 0.31 (8%) 0.533 composite
🏆 ChallengeBreaking the GBA—α-Synuclein Bidirectional Feedback Loop in Parkinson's Disease$3.0M →

🧪 Overview

Dysbiotic bacteria compromise intestinal barrier integrity through zonulin pathway activation, allowing bacterial antigens and α-synuclein oligomers to enter systemic circulation and seed CNS pathology. Targeted tight junction stabilizers could prevent this peripheral-to-central disease propagation.

🧬 Mechanism

🧬 Curated Mechanism Pathway

Curated pathway from expert analysis

graph TD
    A["Dysbiotic Bacteria<br/>E. coli, gram-negative"]
    B["LPS Endotoxin<br/>Release"]
    C["TLR4 Activation<br/>Inflammatory Signaling"]
    D["MLCK Activation<br/>Phosphorylation"]
    E["Tight Junction<br/>Disruption"]
    F["CLDN1, OCLN, ZO1<br/>Downregulation"]
    G["Gut Barrier<br/>Permeability"]
    H["alpha-Synuclein<br/>Aggregation"]
    I["Vagal Nerve<br/>Transmission"]
    J["CNS alpha-Synuclein<br/>Propagation"]
    K["Neurodegeneration<br/>Progression"]
    L["Tight Junction<br/>Stabilizers"]
    M["Probiotic<br/>Intervention"]

    A -->|"produces"| B
    B -->|"binds"| C
    C -->|"activates"| D
    D -->|"phosphorylates"| E
    E -->|"reduces"| F
    F -->|"increases"| G
    G -->|"promotes"| H
    H -->|"travels via"| I
    I -->|"spreads"| J
    J -->|"causes"| K
    L -->|"stabilizes"| F
    M -->|"restores"| A

    style A fill:#ef5350,color:#0d0d1a
    style B fill:#ef5350,color:#0d0d1a
    style C fill:#ef5350,color:#0d0d1a
    style D fill:#ef5350,color:#0d0d1a
    style E fill:#ef5350,color:#0d0d1a
    style F fill:#ce93d8,color:#0d0d1a
    style G fill:#ef5350,color:#0d0d1a
    style H fill:#ef5350,color:#0d0d1a
    style I fill:#4fc3f7,color:#0d0d1a
    style J fill:#ef5350,color:#0d0d1a
    style K fill:#ffd54f,color:#0d0d1a
    style L fill:#81c784,color:#0d0d1a
    style M fill:#81c784,color:#0d0d1a

⚖️ Evidence

⚖️ Evidence Matrix5 supports2 contradicts
Supports
Macrophage-derived CTSS drives the age-dependent disruption of the blood-CSF barrier.
Neuron2025PMID:40015275medium
Supports
Claudin-1 interacts with EPHA2 to promote cancer stemness and chemoresistance in colorectal cancer.
Cancer Lett2023PMID:37924938medium
Supports
A monoclonal antibody targeting nonjunctional claudin-1 inhibits fibrosis in patient-derived models by modulating cell plasticity.
Sci Transl Med2022PMID:36542691medium
Supports
Streptococcus pneumoniae extracellular vesicles aggravate alveolar epithelial barrier disruption via autophagic degradation of OCLN (occludin).
Autophagy2024PMID:38497494medium
Supports
Benvitimod Inhibits IL-4- and IL-13-Induced Tight Junction Impairment by Activating AHR/ARNT Pathway and Inhibiting STAT6 Phosphorylation in Human Keratinocytes.
J Invest Dermatol2024PMID:37734479medium
Contradicts
The microbiome-gut-brain axis in Parkinson disease remains difficult to translate from mechanistic models to causal human intervention evidence.
Nat Rev Neurol2022PMID:35750883medium
Contradicts
Microbiome-based Parkinson therapies are still experimental with unresolved strain selection, endpoint, and clinical efficacy questions.
Front Nutr2024PMID:39568727medium
📖 Linked Papers (25)Export BibTeX ↗
Figures
Figures
Figures available at source paper (no open-access XML found).
Figures
Figures
Figures available at source paper (no open-access XML found).
No figures
📙 Related Wiki Pages (15)

🏥 Translation

🧬 3D Protein Structure — CLDN1

No curated PDB or AlphaFold mapping for CLDN1 yet. Search RCSB →

🧠 GTEx v10 Brain ExpressionJSON

Median TPM across 13 brain regions for CLDN1, OCLN, ZO1, MLCK from GTEx v10.

Amygdala2.6 Substantia nigra2.5 Hypothalamus2.0 Anterior cingulate cortex BA241.9 Hippocampus1.8 Frontal Cortex BA91.5 Caudate basal ganglia1.2 Nucleus accumbens basal ganglia1.1 Cortex1.1 Spinal cord cervical c-10.9 Putamen basal ganglia0.9 Cerebellar Hemisphere0.5 Cerebellum0.4median TPM (GTEx v10)

💉 Clinical Trials (5)Relevance: 44%

0
Active
0
Completed
282
Total Enrolled
PHASE1
Highest Phase
RECRUITING·NCT04220190 · Rapa Therapeutics LLC
41 enrolled · 2025-01-02 · → 2026-07-01
RAPA-501-ALS is a phase 2/3 expansion cohort study of RAPA-501 autologous hybrid TREG/Th2 cells in patients living with amyotrophic lateral sclerosis (pwALS).
Amyotrophic Lateral Sclerosis
RAPA-501 Autologous T stem cells
COMPLETED·NCT03955380 · Prof. Dr. Dieter Willbold
24 enrolled · 2018-12-12 · → 2019-04-03
This is a single-center multiple-ascending-dose clinical trial assessing the safety and tolerability of oral dosing of Contraloid acetate in healthy volunteers. The study drug Contraloid (alias RD2, a
Alzheimer Dementia Alzheimer Disease
Contraloid
UNKNOWN·NCT04820881 · Washington D.C. Veterans Affairs Medical Center
60 enrolled · 2021-10-01 · → 2024-09
This grant award entitled, "Cerebrovascular Reactivity and Oxygen Metabolism as Markers for Neurodegeneration after Traumatic Brain Injury" (hereafter, "Neurovascular Study"), aims to determine if neu
Neurodegenerative Diseases
NOT_YET_RECRUITING·NCT07212088 · iCamuno Biotherapeutics Ltd.
12 enrolled · 2026-02-28 · → 2027-12-15
Parkinson's disease is a progressive neurodegenerative disorder characterized by high morbidity due to the limited regenerative capacity of dopaminergic neurons in the brain. Current drug treatments p
Parkinson Disease
ALC01 therapy
COMPLETED·NCT02405182 · University of Alberta
145 enrolled · 2014-09 · → 2019-03
Amyotrophic lateral sclerosis (ALS) is a disabling and rapidly progressive neurodegenerative disorder. There is no treatment that significantly slows progression. Increasing age is an important risk f
Amyotrophic Lateral Sclerosis ALS Motor Neuron Diseases
Magnetic Resonance Imaging

No curated ClinVar variants loaded for this hypothesis.

Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.

🔍 Search ClinVar for CLDN1, OCLN, ZO1, MLCK →

No DepMap CRISPR Chronos data found for CLDN1, OCLN, ZO1, MLCK.

Run python3 scripts/backfill_hypothesis_depmap.py to populate.

💰 Estimated Development
Cost
$0
Timeline
2.5 years

🏆 Tournament

🏆 Arenas / Elo

No arena matches recorded yet. Browse Arenas →

📊 Market Indicators

7d Trend
Falling
7d Momentum
▼ 1.6%
Volatility
High
0.0554
Events (7d)
3
Price History
▼24.0%

💾 Resource Usage

LLM Tokens
34,972
$0.2158
Total Cost
$0.2158

🔮 Predictions

🔎 Predictions vs Observations2 predictions · 0 with recorded observations
PredictionPredictedObservedStatusConf
If hypothesis is true, intervention address the upstream inflammatory triggers while tight junction stabilizers provide direct structural support, potentially achieving superior barrier restoration coaddress the upstream inflammatory triggers while tight junction stabilizers provide direct structural support, potentially achieving superior barrier restoratio— no observation —pending0.60
If hypothesis is true, intervention sequester pathological species in the gut, preventing their systemic dissemination even in the presence of barrier dysfunctionsequester pathological species in the gut, preventing their systemic dissemination even in the presence of barrier dysfunction— no observation —pending0.60
🔮 Falsifiable Predictions (2)
pendingconf 60%
If hypothesis is true, intervention address the upstream inflammatory triggers while tight junction stabilizers provide direct structural support, potentially achieving superior barrier restoration compared to either approach alone
Predicted outcome: address the upstream inflammatory triggers while tight junction stabilizers provide direct structural support, potentially achieving superior barrier
Falsification: Intervention fails to address the upstream inflammatory triggers while tight junction stabilizers provide direct structural support, potentially achieving superior barrier restoration compared to eith
pendingconf 60%
If hypothesis is true, intervention sequester pathological species in the gut, preventing their systemic dissemination even in the presence of barrier dysfunction
Predicted outcome: sequester pathological species in the gut, preventing their systemic dissemination even in the presence of barrier dysfunction
Falsification: Intervention fails to sequester pathological species in the gut, preventing their systemic dissemination even in the presence of barrier dysfunction
Metadatasource: v1_phase_c_backfill · origin_type: gap_debate
sourcev1_phase_c_backfill
origin_typegap_debate
_schema_version1
📊 Evidence Profile
Evidence Balance
+0%
Certainty
0%
Debates
0
Incoming
0
Outgoing
0
0 supporting 0 contradicting 0 neutral
Public annotations (0)Annotate on Hypothes.is →
No public annotations yet.